A small Research Triangle Park company developing a promising treatment for multiple sclerosis has won a prestigious award to pay for further research.
Cognosci will use the $330,000 grant to continue evaluating an experimental compound that shows potential in helping rebuild the central nervous system, rather than just blocking damage from MS.
It's not a lot of money for a seven-employee company that's attracted more than $18 million, mostly in federal grants, since it was founded in May 2000. But the award does elevate Cognosci's reputation and could help its leaders land new partnerships.
The money was one of two initial grants handed out by Fast Forward, a nonprofit organization set up by the National MS Society to accelerate the development of promising treatments, and EMD Serono, the subsidiary of a German drug maker that's also working on MS drugs.
Cognosci's grant also includes a license option for EMD Serono. That means that if Cognosci's early testing continues to be successful, EMD could invest more money to help test the drug in patients and commercialize it, said Dale Christensen, left, Cognosci's vice president of research and business development.
"It's really not that long before patients could start seeing benefits," said Christensen, whose father died from MS. "That helps keep our energy up."